• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rev Med Virol . Role of red blood cell distribution width, as a prognostic indicator in COVID-19: A systematic review and meta-analysis

tetano

Editor, Senior Moderator
Rev Med Virol


. 2021 Jun 6;e2264.
doi: 10.1002/rmv.2264. Online ahead of print.
Role of red blood cell distribution width, as a prognostic indicator in COVID-19: A systematic review and meta-analysis


Soumya Sarkar[SUP] 1 [/SUP], Sundara Kannan[SUP] 1 [/SUP], Puneet Khanna[SUP] 1 [/SUP], Akhil Kant Singh[SUP] 1 [/SUP]



Affiliations

Abstract

The red blood cell distribution width (RDW), an indicator of anisocytosis has emerged as a potential tool for risk stratification of critically ill patients with sepsis. Prognostic predictors are of paramount interest for prompt intervention and optimal utilization of the healthcare system in this ongoing context of the Coronavirus Disease 2019 (COVID-19) pandemic. The current systematic review and meta-analysis aims to explore the utility of RDW in the prognosis of COVID-19 patients. A comprehensive screening of electronic databases was performed up to 30th April 2021 after enrolling in PROSPERO (CRD42020206685). Observational studies or interventional studies, evaluating the impact of RDW in COVID-19 outcomes (mortality and severity) are included in this meta-analysis.Our search retrieved 25 studies, with a total of 18,392 and 3,446 COVID-19 patients for mortality and disease severity outcomes. Deceased and critically ill patients had higher RDW levels on admission in comparison to survivors and non-severe patients (SMD = 0.46; 95%CI 0.31-0.71; I[SUP]2[/SUP] = 88% and SMD = 0.46; 95%CI 0.26-0.67; I[SUP]2[/SUP] = 60%, respectively). In a sub-group analysis of 2,980 patients, RDW > 14.5 has been associated with increased risk of mortality (OR = 2.73; 95%CI 1.96-3.82; I[SUP]2[/SUP] = 56%). However, the evidences is of low quality. A higher level of RDW on admission in COVID-19 patients is associated with increased morbidity and mortality. However, further studies regarding the cut-off value of RDW are the need of the hour.

Keywords: Coronavirus Disease 2019; Severe Acute Respiratory Syndrome Coronavirus-2; red blood cell distribution width.
 
Back
Top Bottom